Skip to content
Catalyst

knowcompoundsthiamine

Specimen compound organic compound, cationPlate I

Thiamine

3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2- hydroxyethyl)-4-methylthiazolium chloride.”

Nested hairline contours trace the electron density of one computed shape of thiamine, teal at the edge warming to amber over the atoms.

432 readings, by contour and atom

fig. 1Thiamine · electron density · PubChem CID 1130, computed 3D conformer
Formula
C12H17N4OS+
Molar mass
265.362 g/mol
PubChem CID
1130
InChIKey
JZRWCGZRTZMZEH-UHFFFAOYSA-N

↑ raised 1 finding in 1 endpoint · ↓ lowered 12 in 3 · – no difference found 5 in 4

01 · the evidence, ordered

What the evidence says

Strong
0
Moderate
6
Limited
2
Very limited
10
Insufficient
0

How to read these marks

Fig. 2 Thiamine CHEBI:18385 6 endpoints 18 findings
×1.60
Labels
CompoundInspector

Thiamine

Most findings

  • All-cause mortality×12
  • Intensive care unit length of stay×2
  • Fasting blood glucose×1
  • Glycated haemoglobin (HbA1c)×1
  • Incidence of ICU delirium×1
  • Subjective fatigue×1

18 reference statements, not drawn · 36 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

  1. All-cause mortalitycontested
  2. Fasting blood glucose
  3. Glycated haemoglobin (HbA1c)
  4. Intensive care unit length of staycontested
  5. Incidence of ICU delirium
  6. Subjective fatigue
fig. 3 · 6 endpoints · 18 findingscontested · an endpoint whose findings disagree

02 · contested · 2 endpoints

Where the findings disagree

  1. 0112 findings

    All-cause mortality

    ↓ lowered
    10
    – no difference found
    2
  2. 022 findings

    Intensive care unit length of stay

    – no difference found
    1
    ↑ raised
    1

03 · findings

What thiamine moved, and by how much

  • OR odds ratio · MD mean difference · HR hazard ratio · SMD standardised mean difference. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
Direction
Strength, at least

12 of 18 shown

  1. All-cause mortalitycontestedMoved: lowersEffect, as reportedOR0.37[0.18 to 0.78]Evidence: Moderatereplicated ×9Paper: PMID 341932352021
    Who
    Critically ill adults with COVID-19 in two ICUs, retrospective cohort; adjunctive thiamine versus none, propensity-score matched (83 pairs); horizon is 30 days
    Dose studied
    not reported

    In other words, patients who received thiamine as adjunctive therapy during ICU stay had a lower 30-day mortality rate by 63% [OR (95% CI): 0.37 (0.18, 0.78), P value = 0.009] (Table 1).”

    Quoted verbatim from Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study.cohortPermalink
  2. Fasting blood glucoseMoved: no difference foundEffect, as reportedMD−0.2[−0.69 to 0.29]Evidence: ModeratePaper: PMID 360080642022
    Who
    Adults with type 2 diabetes; three pooled placebo-controlled trials; follow-up under 3 months
    Dose studied
    not reported

    Pooled results from three trials demonstrated no statistically significant difference in the FBG level between those who received thiamine supplementation versus placebo after less than 3 months of follow-up (MD, −0.20 mmol/L; CI: −0.69 to 0.29).”

    Quoted verbatim from Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.meta-analysisPermalink
  3. All-cause mortalitycontestedMoved: lowersEvidence: Moderatereplicated ×9Paper: PMID 288509302018
    Who
    Adults with septic shock and alcohol use disorder in an ICU (retrospective, unadjusted comparison); thiamine-treated patients versus patients given no thiamine; routes pooled (68% of initial doses parenteral, remainder oral)
    Dose studied
    most commonly 100 mg per dose

    We found a significantly lower mortality for those receiving thiamine compared to those not receiving thiamine (15 [44%] vs. 15 [79%], p = 0.02, Table 2).”

    Quoted verbatim from Thiamine in septic shock patients with alcohol use disorders: An observational pilot study.cohortPermalink
  4. All-cause mortalitycontestedMoved: lowersEvidence: Moderatereplicated ×9Paper: PMID 418724382026
    Who
    Adult ICU patients with sepsis-associated delirium (Sepsis-3, MIMIC-IV, liver disease excluded); 332 received thiamine, 956 did not; crude unadjusted analysis, 30-day follow-up
    Dose studied
    not reported

    In crude analysis, thiamine use was associated with a lower risk of 30-day mortality.”

    Quoted verbatim from Association of thiamine supplementation with 30-day mortality among ICU patients with sepsis-associated delirium.cohort · 4 weeksPermalink
  5. Glycated haemoglobin (HbA1c)Moved: no difference foundEffect, as reportedMD−0.02[−0.35 to 0.31]Evidence: ModeratePaper: PMID 360080642022
    Who
    Adults with type 2 diabetes; two pooled placebo-controlled trials; follow-up under 3 months
    Dose studied
    not reported

    Two trials that investigated the effect of thiamine supplementation versus placebo on HbA1c levels demonstrated no statistically significant differences between the groups at less than 3-month follow-up period (mean difference, MD: −0.02%, 95% CI: −0.35 to 0.31).”

    Quoted verbatim from Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.meta-analysisPermalink
  6. All-cause mortalitycontestedMoved: lowersEffect, as reportedHR0.8[0.67 to 0.94]Evidence: Moderatereplicated ×9Paper: PMID 396143572024
    Who
    Adult ICU patients with sepsis or septic shock at two Swiss university hospitals, 2012-2022; B1 group (n = 1054) versus control group on standard treatment without B1 or ascorbic acid (n = 2183); oral and intravenous thiamine pooled; all clusters combined; all-cause in-hospital mortality
    Dose studied
    not reported

    Overall in-hospital mortality was not the same across the three treatment groups, with a lower mortality observed in patients in group B1 compared to the control group (hazard ratio 0.8, 95% confidence interval [0.67;0.94], p = 0.008, Fig. 1 and Supplementary Fig. 2).”

    Quoted verbatim from Differential effects of thiamine and ascorbic acid in clusters of septic patients identified by latent variable analysis.cohortPermalink
  7. All-cause mortalitycontestedMoved: lowersEvidence: Limitedreplicated ×9Paper: PMID 362594602023
    Who
    Adults with Sepsis-3 in the MIMIC-IV intensive care database, retrospective cohort; intravenous thiamine in ICU versus none; confounder-adjusted Cox model; horizon is ICU stay
    Dose studied
    not reported

    In comparison with the TUR group, the TR group had a statistically significantly lower risk of ICU mortality.”

    Quoted verbatim from Thiamine supplementation may be associated with improved prognosis in patients with sepsis.cohortPermalink
  8. All-cause mortalitycontestedMoved: lowersEffect, as reportedHR0.82[0.69 to 0.98]Evidence: Limitedreplicated ×9Paper: PMID 411847852025
    Who
    Critically ill patients with cerebrovascular disease in the MIMIC-IV database, propensity-score-matched thiamine users and non-users (1,585 matched pairs); 28-day all-cause mortality shown
    Dose studied
    not reported

    With 1,585 matched pairs post-PSM, thiamine administration showed a significant association with decreased mortality at 7 days (HR = 0.68, 95%CI: 0.53-0.89, P = 0.004), 14 days (HR = 0.78, 95%CI: 0.64-0.96, P = 0.016), and 28 days (HR = 0.82, 95%CI: 0.69-0.98, P = 0.028) compared with non-thiamine use after adjustment.”

    Quoted verbatim from Thiamine use and short-term prognosis in critical cerebrovascular disease: a propensity score matched retrospective analysis from the MIMIC-IV database.cohort · 4 weeksPermalink
  9. All-cause mortalitycontestedMoved: lowersEvidence: Very limitedreplicated ×9Paper: PMID 422519132026
    Who
    Critically ill adults with sepsis-associated acute respiratory failure in the MIMIC-IV database; thiamine supplementation versus no thiamine, retrospective
    Dose studied
    not reported

    Thiamine supplementation was independently associated with reduced in-hospital and ICU mortality in critically ill patients with sepsis-associated acute respiratory failure, particularly in the elderly.”

    Quoted verbatim from The association between thiamine use and mortality in critically ill patients with sepsis-associated acute respiratory failure: A retrospective analysis of the MIMIC-IV database.cohortPermalink
  10. Incidence of ICU deliriumMoved: lowersEffect, as reportedOR0.58[0.34 to 0.98]Evidence: Very limitedPaper: PMID 341185012021
    Who
    Critically ill patients; RCT-only subset of a meta-analysis that also pooled cohort studies, thiamine versus standard of care
    Dose studied
    not reported

    In the analysis of RCTs, thiamine supplementation showed 42% lower odds of developing ICU delirium (OR 0.58, 95% CI, 0.34-0.98).”

    Quoted verbatim from Effect of thiamine supplementation in critically ill patients: A systematic review and meta-analysis.meta-analysisPermalink
  11. All-cause mortalitycontestedMoved: no difference foundEffect, as reportedOR0.87[0.62 to 1.21]Evidence: Very limitedreplicated ×1Paper: PMID 330368542020
    Who
    Patients with septic shock; pooled four randomized controlled trials of intravenous thiamine
    Dose studied
    not reported

    Overall, compared with control group in patients with septic shock, intravenous thiamine revealed no substantial impact on mortality (odd ratio [OR] = 0.87; 95% confidence interval [CI) = 0.62 to 1.21; P = 0.40), lactate change (standard mean difference [SMD] = 0.04; 95% CI = -0.28 to 0.35; P = 0.82), Sequential Organ Failure Assessment (SOFA) change (SMD = 0.02; 95% CI = -0.18 to 0.21; P = 0.87), intensive care unit (ICU) stay (SMD = -0.02; 95% CI = -0.33 to 0.30; P = 0.90) or renal replacement therapy (OR = 0.47; 95% CI = 0.07 to 3.15; P = 0.43).”

    Quoted verbatim from Intravenous thiamine for septic shock: A meta-analysis of randomized controlled trials.meta-analysisPermalink
  12. Intensive care unit length of staycontestedMoved: raisesEffect, as reportedMD0.4[0.01 to 0.79]Evidence: Very limitedPaper: PMID 393070942024
    Who
    Critically ill patients; meta-analysis of randomized controlled trials of intravenous thiamine
    Dose studied
    not reported

    Conversely, thiamine administration resulted in a slight increase in the length of ICU stay (MD, 0.40 days; 95% CI, 0.01-0.79 days; High CoE).”

    Quoted verbatim from Effect of intravenous thiamine administration on critically ill patients: A systematic review and meta-analysis of randomized controlled trials.meta-analysisPermalink

No dose is advised.

  • OR odds ratio · MD mean difference · HR hazard ratio · SMD standardised mean difference. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed

04 · identity

Structure

fig. 4Thiamine · 2D structure · ChEBI’s SMILES
fig. 5Thiamine · 3D conformer · PubChem CID 1130, computed
Charge
+1
SMILES
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1

05 · figures · 2 plates

Plates

  • Hairline isopotential curves around one computed shape of thiamine, teal where the potential is negative and amber where it is positive.
    fig. 6Thiamine · electrostatic potential, molecular plane · PubChem CID 1130, computed 3D conformer
  • A dial of hairlines, each a peak of thiamine's measured mass spectrum, its angle the peak's mass-to-charge ratio and its length the peak's intensity.
    fig. 7Thiamine · MS [M]+ LC-ESI-QQQ positive · MassBank MSBNK-RIKEN_NPDepo-CB000299 (Nogawa T, CC BY)

06 · reach

What it touches on the way

7 entities · assembled from reference reactions

  1. SLC47A1Protein17 paths · 16 endpointsinferred
  2. TPK1Protein10 paths · 5 endpointsinferred
  3. SLC19A3Protein6 paths · 2 endpointsinferred
  4. SLC22A2Protein5 paths · 5 endpointsinferred
  5. SLC22A1Protein3 paths · 3 endpointsinferred
  6. SLC19A2Protein3 paths · 1 endpointinferred
  7. SLC47A2Protein1 path · 1 endpointinferred

Where it reaches

8 regions · transporter routes

  1. Female reproductivereproductive2 routesinferred
  2. Liverdigestive2 routesinferred
  3. Adrenal glandendocrine1 routeinferred
  4. Airway and sinusesrespiratory1 routeinferred
  5. Colon and rectumdigestive1 routeinferred
  6. Kidneyurinary1 routeinferred
  7. Lungrespiratory1 routeinferred
  8. Small intestinedigestive1 routeinferred

07 · documented · reference

Interactions

Documented interactions
None reported

Pairs that share biology

What the reference databases state

Liver injury · LiverTox
EUnlikely cause of liver injury
NBK547852 · transcribed, not assessed
Reference statements
1801 ProteinSLC19A2, SLC19A3, SLC22A1, SLC22A15, SLC22A2, SLC35F3, and 3 more02 Compoundthiamine diphosphate, thiamine(1+) diphosphateinferred, one hop from thiamine
Reactions · Rhea
18reactions
18Reference statements

What the reference databases state

Evidence key

Regulatory determinations

  • LiverTox likelihood score ELiverTox

    LiverTox Likelihood Score E — despite extensive use, no evidence that the agent has caused liver injury. Chapter: "Vitamin B". Source: LiverTox Master List (NBK571102).

    The document·Public Domain (NLM/NIH)·Transcribed, not assessed

Statements

18 statements

2 of 3 reference databases · Sources: Human-GEM, Rhea

1242thiamine18 STATEMENTS
18Reactions

08 · on the label · 9,891 products

Labelled products

Source: NIH DSLD · Ingredient: thiamine · 9,891 products · Declared amount per serving (the first 1,000 shown): 0.02–500 mg

964 labels of the first 1,000 shown state an amount36 do not

  • 1st PhormM-Factor HeroThiamin, as Thiamine Mononitrate, Vitamin B150 mgper 3 capsulesDSLD:12881
  • 21 Super-VitaVitamins With Minerals Tablets (21 Vitamins And Minerals)2.5 mgper 1 tabletDSLD:13537
  • 21st CenturyDiabetic Support FormulaThiamine Mononitrate1.5 mgper 3 tabletsDSLD:11189
  • 21st CenturyOne Daily ActiveThiamin, Thiamine Mononitrate, as Thiamin Mononitrate4.5 mgper 1 tabletDSLD:11548
  • 21st CenturyOne Daily Adults 50+Thiamin, Thiamine Mononitrate, as Thiamin Mononitrate4.5 mgper 1 tabletDSLD:11549
  • 21st CenturyOne Daily Cholesterol Health With PolicosanolVitamin B11.5 mgper 1 tabletDSLD:11550
  • 21st CenturyOne Daily EnergyThiamin, Thiamine Mononitrate, as Thiamin Mononitrate3 mgper 1 tabletDSLD:11552
  • 21st CenturyOne Daily EssentialThiamin, Thiamine Mononitrate, as Thiamin Mononitrate1.5 mgper 1 tabletDSLD:11556
  • 21st CenturyOne Daily MaximumThiamin, Thiamine Mononitrate, as Thiamin Mononitrate1.5 mgper 1 tabletDSLD:11558
  • 21st CenturyOne Daily Men's HealthThiamin, Thiamine Mononitrate, as Thiamin Mononitrate1.2 mgper 1 tabletDSLD:11559
  • 21st CenturyOne Daily Weight ControlThiamin, Thiamine Mononitrate, as Thiamin Mononitrate1.9 mgper 1 tabletDSLD:11560
  • 21st CenturyOne Daily Women'sThiamin, Thiamine Mononitrate, as Thiamin Mononitrate1.5 mgper 1 tabletDSLD:11561
Show the remaining 9,879Show the first 12

Label record: NIH Office of Dietary Supplements · CC0

09 · the record

Sources

512

papers screened for thiamine

admitted
17
read and discarded
376
not read yet
119

The screening record, every paper and why

Sources cited

16 papers · 18 findings

1 admitted at screening, no finding yet

Show every paper citedHide the papers cited

Other names · 10

3-(4-AMINO-2-METHYL-PYRIMIDIN-5-YLMETHYL)-5-(2-HYDROXY-ETHYL)-4-METHYL-THIAZOL-3-IUM · Aneurin · Antiberiberi factor · Thiamin · thiamine cation · thiamine ion · thiamine(1+) ion · thiaminium · Vitamin B1

systematic · 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium